As the first oral small‐molecule selective inhibitor of TGF‐β1, galunisertib has been proved to have anti‐tumor effects in clinical trials of liver cancer, pancreatic cancer, and glioma.331, 332, 333. The gene discussed is TGFB1; the disease is familial pancreatic carcinoma.